Soliman, A.; Rodriguez-Vera, L.; Alarcia-Lacalle, A.; Pippa, L.F.; Subhani, S.; Lukacova, V.; Duconge, J.; de Moraes, N.V.; Vozmediano, V.
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling. Pharmaceutics 2025, 17, 373.
https://doi.org/10.3390/pharmaceutics17030373
AMA Style
Soliman A, Rodriguez-Vera L, Alarcia-Lacalle A, Pippa LF, Subhani S, Lukacova V, Duconge J, de Moraes NV, Vozmediano V.
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling. Pharmaceutics. 2025; 17(3):373.
https://doi.org/10.3390/pharmaceutics17030373
Chicago/Turabian Style
Soliman, Amira, Leyanis Rodriguez-Vera, Ana Alarcia-Lacalle, Leandro F. Pippa, Saima Subhani, Viera Lukacova, Jorge Duconge, Natalia V. de Moraes, and Valvanera Vozmediano.
2025. "Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling" Pharmaceutics 17, no. 3: 373.
https://doi.org/10.3390/pharmaceutics17030373
APA Style
Soliman, A., Rodriguez-Vera, L., Alarcia-Lacalle, A., Pippa, L. F., Subhani, S., Lukacova, V., Duconge, J., de Moraes, N. V., & Vozmediano, V.
(2025). Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling. Pharmaceutics, 17(3), 373.
https://doi.org/10.3390/pharmaceutics17030373
